Dr Laura Green, MBBS, MD(Res), FRCP, FRCPath
Senior Clinical Lecturer in Transfusion Research and Innovation; Consultant in Haemostasis and Transfusion Medicine
Centre: Centre for Neuroscience, Surgery and Trauma
Laura Green is a Senior Clinical Lecturer in Transfusion Research and Innovation at the Blizard Institute, Barts and the London School of Medicine & Dentistry, Queen Mary University of London. She graduated from Medical School in Albania in 1998 and entered the specialist training in Haematology at Kings College Hospital in 2004. She went on to undertake research in Haemostasis and Thrombosis at University College London leading to the degree of MD(Res). In 2011 she was appointed a Consultant in Haemostasis and Transfusion Medicine, with joint appointments at NHS Blood and Transplant and Barts Health Trust.
Her main research centres on generating the evidence to inform the appropriate use of blood components for the treatment of a range of acquired bleeding disorders (e.g. cardiac surgery, obstetrics etc.) and bridging laboratory research and clinical work by developing new blood component that can improve the management of bleeding disorders.
My main interest is in pragmatic randomised controlled trials, and translation research related to blood components. I have led several national studies/initiatives to understand and improve transfusion management of bleeding patients. Examples include:
- Red Cell and Plasma study part of Whole Blood program for use in bleeding trauma patients in pre-hospital setting,
- PROPHESY trial (a pragmatic pilot randomised control trial of Prothrombin Complex Concentrates versus Fresh Frozen Plasma in adult patients who are undergoing Heart Surgery),
- ACROBAT trial (the effect of early cryoprecipitate transfusion versus routine care in women who develop severe postpartum haemorrhage: A pilot cluster randomised control trial).
- ORANGE study (oral anticoagulant agent-associated bleeding events reporting system – UK wide)
- UK-obstetric study (epidemiology and outcome of massive transfusion in PPH)
I am also co-investigator in two NIHR-funded projects: the development of universal plasma for NHS hospitals; and early cryoprecipitate in major bleeding in trauma (CRYOSTAT-2 trial).
Zaidi A., Kohli R., Daru J., Estcourt L., Khan K., Thangaratinam Sh., Green L. Early use of fibrinogen replacement therapy in postpartum haemorrhage – a systematic review. Transf. Med Review Jan 28. doi: 10.1016/j.tmrv.2019.12.002. [Epub ahead of print]
Cole E, Weaver A, Gall L, West A, Nevin D, Tallach R, O'Neill B, Lahiri S, Allard S, Tai N, Davenport R, Green L, Brohi K. A Decade of Damage Control Resuscitation: New Transfusion Practice, New Survivors, New Directions. Ann Surg. 2019 Oct 22.
Rehn M, Weaver A, Brohi K, Eshelby S, Green L, and Lockey DJ. Effect of pre-hospital red blood cell transfusion on mortality and time of death in civilian trauma patients. Shock. 2019 Mar;51(3):284-288
Green L, Bolton-Maggs P, Beattie C, Cardigan R, Kallis Y, Stanworth SJ, Thachil J, Zahra S. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. Br J Haematol. 2018 Apr;181(1):54-67. doi: 10.1111/bjh.15167. Epub 2018 Mar 12
Green L, Tan J, Morris JK, Alikhan R, Curry N, Everington T, Mclean R, Saja K, Stanworth S, Tait C, MacCallum P. A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). Haematologica. 2018 Apr;103(4):738-745
I am supervising several PhD/MD students - a common research theme of their research is better understanding of the coagulation abnormalities associated with different types of bleeding, with a view to testing targeted interventions through future trials.